Bristol-Myers Squibb: Recent Gains Impress, But Tricky Tests Lie Ahead (NYSE:BMY)

Frank Brennan/iStock Editorial via Getty Images Investment Overview: My Thesis on BMY Outlined Post Q3 Earnings After Bristol-Myers Squibb Company ( BMY ) shared its Q3 2025 earnings results at the end of October, I covered the company in a Frank Brennan/iStock Editorial via Getty Images After Bristol-Myers Squibb Company ( BMY ) shared its Q3 2025 earnings results at the end of October, I covered the company in a Analyst’s Disclosure: I/we have a beneficial long position in the shares of BMY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~217 words